Cargando…

Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study

INTRODUCTION: This study was designed to assess real-world outcomes of patients with multiple sclerosis (MS) who were stable on interferon (IFN) beta therapy in the year prior to switching to another IFN beta therapy versus those who continued on the initial treatment. METHODS: This study used admin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohan, Stanley, Smoot, Kyle, Kresa-Reahl, Kiren, Garland, Robert, Yeh, Wei-Shi, Wu, Ning, Watson, Crystal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223975/ https://www.ncbi.nlm.nih.gov/pubmed/30341505 http://dx.doi.org/10.1007/s12325-018-0799-5

Ejemplares similares

Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon
por: Chen, Chao, et al.
Publicado: (2018)

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
por: Cohan, Stanley L., et al.
Publicado: (2021)

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Results from Patient Interviews on Fatigue in Progressive Multiple Sclerosis and Evaluation of Fatigue Patient-Reported Outcome (PRO) Instruments
por: Watson, Crystal, et al.
Publicado: (2022)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
por: Watson, Crystal, et al.
Publicado: (2023)

Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
por: van Beers, Miranda M. C., et al.
Publicado: (2011)

Multiple human beta interferon genes
Publicado: (1982)

Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251
por: Gay, Wilfried, et al.
Publicado: (2004)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
por: Wittling, Megen C., et al.
Publicado: (2021)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE
por: Cohan, Stanley, et al.
Publicado: (2017)

Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis
por: Baghizadeh, Somayyeh, et al.
Publicado: (2016)

Comparative evaluation of patients’ and physicians’ satisfaction with interferon beta-1b therapy
por: Zettl, Uwe Klaus, et al.
Publicado: (2016)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Results of sustained long-term use of interferon beta-1a in a community-based cohort of patients with relapsing multiple sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
por: Sainz, Bruno, et al.
Publicado: (2005)

Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection
por: Schwerdtfeger, Mara, et al.
Publicado: (2022)

Inhibition of suppressor T lymphocytes by murine interferon beta
Publicado: (1987)

Thrombotic microangiopathy associated with use of interferon-beta
por: Olea, Teresa, et al.
Publicado: (2012)

Interferon beta-1a–induced morphea
por: Bezalel, Spencer A., et al.
Publicado: (2014)

Interferon beta-1b for COVID-19
por: Shalhoub, Sarah
Publicado: (2020)

Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta
Publicado: (1988)

Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study
por: Jacques, F., et al.
Publicado: (2012)

Reply to Dorgham et al., “Considering Personalized Interferon Beta Therapy for COVID-19”
por: Davoudi-Monfared, Effat, et al.
Publicado: (2021)

Addressing the targeting range of the ABILHAND-56 in relapsing–remitting multiple sclerosis: A mixed methods psychometric study
por: Cleanthous, Sophie, et al.
Publicado: (2018)

Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study
por: Strzok, Sara, et al.
Publicado: (2018)

Acute posterior reversible encephalopathy syndrome (PRES) in setting of interferon-beta use: case presentation with reduction of edema in 72 h after cessation of interferon-beta therapy with sub-clinical inflammation
por: Dietz, Nicholas, et al.
Publicado: (2021)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Transient oscillatory dynamics of interferon beta signaling in macrophages
por: Pertsovskaya, Inna, et al.
Publicado: (2013)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

Shortcomings in Pharmacy Benefit Forecasting - Interferon Beta Products
por: Rich, Sheldon
Publicado: (2003)

Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
por: Fujimaki, Takamitsu, et al.
Publicado: (2007)

Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis
por: Rajendran, Ranjithkumar, et al.
Publicado: (2022)

Interferon beta, a cofactor in the interferon gamma production induced by gram-negative bacteria in mice
Publicado: (1995)

Reversible therapy-related dysplastic hematopoiesis following Beta Interferon Therapy in Multiple Sclerosis Patients: Report of 2 Cases
por: Nabavi, Seyed Massood, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3403ecmulogj5650osv893hvth